Render Target: SSR
Render Timestamp: 2024-12-19T20:41:51.009Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-12-13 16:05:09.514
Product last modified at: 2024-12-14T08:00:57.024Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Concanamycin A #29442

    Product Information

    Product Usage Information

    Concanamycin A is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 10 μg of powder in 1.15 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 866.1 g/mol
    Purity >98%
    Molecular Formula C46H75NO14
    CAS 80890-47-7
    Solubility Soluble in DMSO at 50 mg/mL.

    Background

    Concanamycin A is a macrolide antibiotic derived from S. diastatochromogenes that is effective against several fungi and yeasts (1). Concanamycin A is an exceptionally potent and specific inhibitor of the ATP-driven proton pumps known as vacuolar type H+-ATPases (V-ATPases). V-ATPases acidify intracellular compartments and translocate protons across the plasma membrane. Intracellular V-ATPases play an important role in endocytosis and intracellular membrane trafficking, while plasma membrane V-ATPases are important in processes such as urinary acidification and bone resorption (2). Treatment of murine cells with Concanamycin A results in apoptosis, evidenced by an increase in fragmented DNA and the number of apoptotic cells with hypodiploid DNA (3). Concanamycin A induced production of nitric oxide and decreased cell growth and survival in mouse leukemic monocyte cells (4). Concanamycin A reversed the downregulation of cell surface MHC-I by the HIV-encoded accessory protein Nef, suggesting a possible therapeutic role of Concanamycin A in enhancing the immune-mediated clearance of HIV-infected cells (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.